Results of Annual General Meeting
27 Mai 2021 - 7:32PM
Business Wire
The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC,
LSE: PRTC) (“PureTech Health” or the “Company”) was held at 11 a.m.
EDT/4 p.m. BST on Thursday, May 27, 2021. All of the resolutions
proposed at the Annual General Meeting were duly passed by the
shareholders on a poll.
The results of the poll, incorporating the proxy votes lodged in
advance of the meeting, are set out below.
Resolutions
For
%
Against
%
Withheld
Total votes cast
001. To approve the Company’s Annual
Report and Accounts for year ended 31 December 2020
225,240,798
100.00%
10,921
0.00%
273,846
225,251,719
002. To approve the Directors’
Remuneration Report
200,319,991
89.74%
22,895,826
10.26%
2,309,748
223,215,817
003. To approve the Directors’
Remuneration Policy
187,285,809
83.90%
35,930,008
16.10%
2,309,748
223,215,817
004. To elect Dr. Raju Kucherlapati as a
director
222,659,203
98.73%
2,865,525
1.27%
837
225,524,728
005. To elect Dr. John LaMattina as a
director
218,438,727
96.86%
7,086,001
3.14%
837
225,524,728
006. To elect Ms. Kiran Mazumdar-Shaw as a
director
189,257,653
84.32%
35,193,037
15.68%
1,074,875
224,450,690
007. To elect Dame Marjorie Scardino as a
director
222,228,072
98.54%
3,296,656
1.46%
837
225,524,728
008. To elect Mr. Christopher Viehbacher
as a director
199,985,210
88.68%
25,539,518
11.32%
837
225,524,728
009. To elect Dr. Robert Langer as a
director
218,164,180
96.74%
7,360,548
3.26%
837
225,524,728
010. To elect Ms. Daphne Zohar as a
director
225,474,510
99.98%
50,218
0.02%
837
225,524,728
011. To elect Dr. Bharatt Chowrira as a
director
225,473,830
99.98%
50,898
0.02%
837
225,524,728
012. To reappoint KPMG LLP as Auditors of
the Company
225,291,096
99.90%
234,469
0.10%
0
225,525,565
013. To authorize the Audit Committee to
determine the Auditors' remuneration
225,483,695
99.98%
41,870
0.02%
0
225,525,565
014. To authorize the allotment of
shares
221,538,872
98.23%
3,986,693
1.77%
0
225,525,565
015. To disapply pre-emption rights
225,102,915
99.81%
422,650
0.19%
0
225,525,565
016. To further disapply pre-emption
rights for acquisitions and specified capital investments.
215,316,258
95.47%
10,209,307
4.53%
0
225,525,565
017. To authorize market purchase of own
shares
225,235,005
99.89%
258,692
0.11%
31,868
225,493,697
018. To authorize general meetings to be
called on not less than 14 clear days’ notice
222,063,258
98.46%
3,462,307
1.54%
0
225,525,565
Notes:
(1)
A vote “Withheld” is not a vote in law and is not counted in the
calculation of the votes “For” or “Against” a resolution.
(2)
As at May 27, 2021 the number of issued shares in the Company
was 286,018,538 ordinary shares, which was the total number of
shares entitling the holders to attend and vote for or against all
the resolutions at the AGM. In accordance with the Company’s
Articles of Association, on a poll every member present in person
or by proxy has one vote for every share held.
(3)
The full text of the resolutions may be found in the Notice of
the Annual General Meeting, copies of which are available on both
the Company’s website
https://investors.puretechhealth.com/financials-filings/reports and
on the National Storage Mechanism.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
inflammatory, fibrotic and immunological conditions, intractable
cancers, lymphatic and gastrointestinal diseases and neurological
and neuropsychological disorders, among others. The Company has
created a broad and deep pipeline through the expertise of its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders. This pipeline,
which is being advanced both internally and through PureTech’s
Founded Entities, is comprised of 26 therapeutics and therapeutic
candidates, including two that have received FDA clearance and
European marketing authorization, as of the date of PureTech’s most
recently filed Annual Report on Form 20-F. All of the underlying
programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation points
based on the Company’s unique insights into the biology of the
brain, immune and gut, or BIG, systems and the interface between
those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210527005783/en/
Investors Allison Mead Talbot +1 617 651 3156
amt@puretechhealth.com
PureTech Health (NASDAQ:PRTC)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
PureTech Health (NASDAQ:PRTC)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024